--News Direct--
Context Therapeutics CEO Marty Lehr joins Proactive's Natalie Stoberman to discuss CTIM-76 preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Lehr noted the latest CTIM-76 bispecific antibody data and developments were shared with investors and colleagues as Context prepares for an Investigational New Drug application filing in early 2024.
CTIM-76 is a Claudin 6 (CLDN6) X CD3 bispecific antibody currently in preclinical development that is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CLDN6 is expressed in multiple solid tumors, including ovarian, lung, and testicular cancers.
The R&D webinar presentation can be found here: https://ir.contexttherapeutics.com/static-files/9377e4ba-bce3-4daa-a4f5-708b6a7c61dc
Contact DetailsProactive Investors USA
+1 347-449-0879
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/context-therapeutics-ctim-76-bispecific-antibody-preclinical-data-presented-at-aacr-annual-meeting-706192599
